Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Cash & Equivalents (2016 - 2025)

Surgery Partners (SGRY) has disclosed Cash & Equivalents for 13 consecutive years, with $239.9 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 10.98% to $239.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $239.9 million through Dec 2025, down 10.98% year-over-year, with the annual reading at $239.9 million for FY2025, 10.98% down from the prior year.
  • Cash & Equivalents hit $239.9 million in Q4 2025 for Surgery Partners, up from $203.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $541.9 million in Q1 2021 to a low of $154.8 million in Q3 2022.
  • Historically, Cash & Equivalents has averaged $271.9 million across 5 years, with a median of $238.0 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: soared 178.47% in 2021 and later plummeted 53.15% in 2022.
  • Year by year, Cash & Equivalents stood at $389.9 million in 2021, then fell by 27.44% to $282.9 million in 2022, then crashed by 30.75% to $195.9 million in 2023, then soared by 37.57% to $269.5 million in 2024, then fell by 10.98% to $239.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for SGRY at $239.9 million in Q4 2025, $203.4 million in Q3 2025, and $250.1 million in Q2 2025.